Physician profile
Ajay T Patel
NPI 1023078912
$6,133.89
in general payments reported to CMS, 2019-2025
22 companies · $541 in 2025
The $541 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,389 · 2020: $474 · 2021: $1,238 · 2022: $909 · 2023: $660 · 2024: $923 · 2025: $541.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,123.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,521.03 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $767.99 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $717.90 | 2021-2024 | |
| Biohaven Pharmaceuticals, INC. | $598.54 | 2021 | |
| Novo Nordisk INC | $569.29 | 2019-2024 | Rybelsus, Ozempic |
| Lilly USA, LLC | $355.56 | 2019-2024 | Jardiance |
| Amgen INC. | $278.32 | 2019-2024 | Repatha, Otezla |
| Amarin Pharma, INC. | $233.91 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $232.89 | 2019-2021 | |
| Lexicon Pharmaceuticals, INC. | $125.00 | 2024 | Inpefa |
| Sanofi-Aventis U.S. LLC | $110.85 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.83 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $83.89 | 2023-2024 | Xifaxan |
| Teva Pharmaceuticals USA, INC. | $79.02 | 2019 | |
| Pfizer INC. | $77.00 | 2019-2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $54.87 | 2020-2022 | |
| Abbott Laboratories | $53.76 | 2021-2022 | |
| Redhill Biopharma INC. | $48.57 | 2020 | |
| Novartis Pharmaceuticals Corporation | $47.25 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $41.64 | 2021-2025 | Eliquis |
| Sumitomo Pharma America, INC. | $30.03 | 2024 | Gemtesa |
| Horizon Therapeutics Plc | $19.75 | 2023 | Krystexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ajay Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.